These data indicated that AAGL stimulates splenic lymphocytes to infiltrate into the liver and thus may contribute to overcoming the barrier of low lymphocyte count in the tumor microenvironment and to enhancing the anti-PD-1 therapy effect in liver cancer. This evidence concerns the gene PDCD1 and liver cancer.